Physician profile
John Frederick Lucas
NPI 1205803301
$4,185.58
in general payments reported to CMS, 2019-2025
43 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $264 · 2021: $173 · 2022: $276 · 2023: $859 · 2024: $892 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.78 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $414.79 | 2019-2025 | |
| Novo Nordisk INC | $391.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $295.22 | 2023-2025 | Veozah, Myrbetriq, Vesicare |
| Pfizer INC. | $256.66 | 2020-2025 | |
| Lilly USA, LLC | $247.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $239.31 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $230.48 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $214.29 | 2019-2025 | Breztri, Airsupra, Flumist Quadrivalent |
| Amgen INC. | $195.78 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $194.14 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $186.23 | 2023-2024 | Austedo Xr, Austedo, Ajovy |
| Galderma Laboratories, L.P. | $129.51 | 2019-2024 | |
| Inspire Medical Systems, INC. | $121.52 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.38 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $94.29 | 2019-2023 | Xarelto |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.